ADAG
Adagene, Inc.
NASDAQ · Healthcare · Biotechnology · CN
$3.31
−1.78%Next report
Analyst consensus
- Next report date
- Mar 31, 2027
- EPS estimate
- -$0.21
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.23
- Revenue actual
- $1.6M
- Revenue estimate
- $1.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +15.1%
- Revenue beats (12Q)
- 0
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $8.00
- PT range
- $7.00 – $9.00
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.23 | -$0.23 | In line | $1.6M |
| Apr 1, 2026 | -$0.28 | -$0.07 | Beat 75.00% | $7.7M |
| Mar 24, 2025 | -$0.33 | -$0.55 | Miss -67.69% | $103.2K |
| Jul 25, 2024 | -$0.41 | -$0.19 | Beat 53.03% | — |
| Mar 30, 2024 | — | -$0.19 | — | — |
| Aug 31, 2023 | -$0.38 | -$0.05 | Beat 87.62% | $8.6M |
| Aug 30, 2022 | -$0.65 | -$1.09 | Miss -68.01% | $3.9M |
| Aug 26, 2021 | -$0.39 | -$1.02 | Miss -161.89% | $1.4M |
| Sep 30, 2020 | — | -$0.33 | — | — |
| Dec 31, 2019 | — | -$0.15 | — | $480.0K |
| Mar 30, 2019 | — | -$0.30 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Mar 31, 2027